Work

Pd30-08 Elucidating the Response Rates to Continued Bacillus Calmette-guerin (bcg) in Patients With Bcg Exposed Bladder Cancer: Implications for Clinical Trial Design

FWCI:
Cites:
Cited by:
Related to: 10